Laurion Capital Management LP Invests $21.10 Million in bluebird bio, Inc. (BLUE)
Laurion Capital Management LP bought a new stake in bluebird bio, Inc. (NASDAQ:BLUE) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 200,853 shares of the biotechnology company’s stock, valued at approximately $21,100,000. Laurion Capital Management LP owned approximately 0.44% of bluebird bio at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently modified their holdings of BLUE. BlackRock Inc. raised its stake in shares of bluebird bio by 44,948.0% in the first quarter. BlackRock Inc. now owns 3,182,188 shares of the biotechnology company’s stock valued at $289,259,000 after purchasing an additional 3,175,124 shares in the last quarter. MARSHALL WACE ASIA Ltd acquired a new position in shares of bluebird bio in the first quarter valued at $18,006,000. Marshall Wace North America L.P. acquired a new position in shares of bluebird bio in the first quarter valued at $18,006,000. Baillie Gifford & Co. raised its stake in shares of bluebird bio by 3.8% in the second quarter. Baillie Gifford & Co. now owns 5,400,658 shares of the biotechnology company’s stock valued at $567,339,000 after purchasing an additional 196,025 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of bluebird bio by 4.6% in the first quarter. Vanguard Group Inc. now owns 3,215,246 shares of the biotechnology company’s stock valued at $292,266,000 after purchasing an additional 141,293 shares in the last quarter.
In other news, Director Mark Vachon sold 6,000 shares of the business’s stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $126.82, for a total transaction of $760,920.00. Following the completion of the transaction, the director now owns 8,000 shares of the company’s stock, valued at approximately $1,014,560. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Jeffrey T. Walsh sold 4,900 shares of the business’s stock in a transaction on Monday, September 11th. The stock was sold at an average price of $125.73, for a total value of $616,077.00. Following the transaction, the insider now directly owns 32,205 shares of the company’s stock, valued at approximately $4,049,134.65. The disclosure for this sale can be found here. Insiders have sold a total of 153,248 shares of company stock valued at $17,708,425 in the last three months. 3.90% of the stock is owned by insiders.
A number of research analysts recently commented on the company. BTIG Research restated a “buy” rating and issued a $112.00 target price on shares of bluebird bio in a research note on Thursday, June 1st. Zacks Investment Research lowered bluebird bio from a “buy” rating to a “hold” rating in a research note on Tuesday, July 18th. BidaskClub lowered bluebird bio from a “hold” rating to a “sell” rating in a research note on Wednesday, August 2nd. Jefferies Group LLC restated a “buy” rating and issued a $88.00 target price on shares of bluebird bio in a research note on Friday, August 11th. Finally, Maxim Group upgraded bluebird bio from a “hold” rating to a “buy” rating and set a $100.00 target price for the company in a research note on Friday, June 2nd. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and thirteen have assigned a buy rating to the company. bluebird bio currently has an average rating of “Hold” and an average price target of $107.86.
WARNING: This piece was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.watchlistnews.com/laurion-capital-management-lp-invests-21-10-million-in-bluebird-bio-inc-blue/1566889.html.
Shares of bluebird bio, Inc. (NASDAQ BLUE) traded down 0.19% during mid-day trading on Friday, hitting $131.60. The stock had a trading volume of 1,127,989 shares. The firm’s market cap is $6.00 billion. bluebird bio, Inc. has a 52 week low of $37.05 and a 52 week high of $136.85. The stock has a 50 day moving average price of $106.30 and a 200 day moving average price of $96.34.
bluebird bio (NASDAQ:BLUE) last posted its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.73) EPS for the quarter, missing analysts’ consensus estimates of ($1.66) by ($0.07). bluebird bio had a negative return on equity of 32.19% and a negative net margin of 1,080.59%. The business had revenue of $16.70 million for the quarter, compared to analyst estimates of $6.29 million. During the same period last year, the firm posted ($1.59) EPS. bluebird bio’s quarterly revenue was up 977.4% on a year-over-year basis. Equities research analysts expect that bluebird bio, Inc. will post ($6.84) EPS for the current fiscal year.
About bluebird bio
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bluebird bio, Inc. (NASDAQ:BLUE).
Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.